octreotide injection (SYHX2008)
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 26, 2024
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
(clinicaltrials.gov)
- P2 | N=90 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Endocrine Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Neuroendocrine Tumor • Oncology • Solid Tumor
July 17, 2024
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
(clinicaltrials.gov)
- P2 | N=90 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
New P2 trial • Endocrine Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Neuroendocrine Tumor • Oncology • Solid Tumor
October 10, 2023
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=56 | Completed | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting ➔ Completed
Trial completion • Acromegaly • Endocrine Disorders • IGF1
March 14, 2023
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=56 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Acromegaly • Endocrine Disorders • IGF1
March 09, 2023
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=56 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
New P1 trial • Acromegaly • Endocrine Disorders • IGF1
1 to 5
Of
5
Go to page
1